BioSolix
Research-focused biotechnology company developing and supplying gene delivery technologies and reagents, lipid nanoparticle (LNP) formulation services for RNA/DNA delivery, cell viability assay reagents, and first-in-class anticancer small molecules via drug-repositioning strategies. Operates R&D, product development, and contract formulation services with academic and industry collaborations.
Industries
Nr. of Employees
small (1-50)
BioSolix
Products
Transfection reagent (general-purpose)
Reagent formulated to deliver nucleic acids (pDNA, siRNA, mRNA) into a wide range of cell lines including primary and stem cells with reported high transfection efficiency and low cytotoxicity.
siRNA-optimized transfection reagent
Reagent optimized for siRNA delivery and knockdown experiments with compatibility in serum-containing media and low toxicity.
mRNA-optimized transfection reagent
Reagent specialized for mRNA transfection with reported high efficiency and low cytotoxicity across multiple cell types and compatibility with serum-containing medium.
Reagent for viral (lentiviral) production
Reagent and protocol tailored for high-efficiency transfection in HEK293T to support lentiviral production with demonstrated high titers across plate formats.
One-step transfection reagent (single-step workflow)
Reagent designed for simplified one-step transfection without separate dilution or complex mixing, targeting higher cell viability post-transfection.
Cell Counting Kit-8 (WST-8 based cell viability assay)
Colorimetric cell viability reagent using WST-8 to measure living cell quantity via formazan absorbance at ~450 nm for viability and cytotoxicity assays.
Transfection reagent (general-purpose)
Reagent formulated to deliver nucleic acids (pDNA, siRNA, mRNA) into a wide range of cell lines including primary and stem cells with reported high transfection efficiency and low cytotoxicity.
siRNA-optimized transfection reagent
Reagent optimized for siRNA delivery and knockdown experiments with compatibility in serum-containing media and low toxicity.
mRNA-optimized transfection reagent
Reagent specialized for mRNA transfection with reported high efficiency and low cytotoxicity across multiple cell types and compatibility with serum-containing medium.
Reagent for viral (lentiviral) production
Reagent and protocol tailored for high-efficiency transfection in HEK293T to support lentiviral production with demonstrated high titers across plate formats.
One-step transfection reagent (single-step workflow)
Reagent designed for simplified one-step transfection without separate dilution or complex mixing, targeting higher cell viability post-transfection.
Cell Counting Kit-8 (WST-8 based cell viability assay)
Colorimetric cell viability reagent using WST-8 to measure living cell quantity via formazan absorbance at ~450 nm for viability and cytotoxicity assays.
Services
Contract service to formulate customer-provided RNA into LNPs for in vitro and in vivo experiments, including small-batch and preclinical scale options, with physical characterization and data delivery.
Contract service to formulate customer-provided RNA into LNPs for in vitro and in vivo experiments, including small-batch and preclinical scale options, with physical characterization and data delivery.
Expertise Areas
- Gene delivery systems
- Lipid nanoparticle formulation and encapsulation
- Transfection reagent development for DNA/RNA/mRNA/siRNA
- Preclinical small-molecule anticancer development (drug repositioning)
Key Technologies
- Lipid nanoparticle (LNP) formulation
- Microfluidics-based nanoparticle manufacturing
- Nanohybrid transfection reagent formulation
- mRNA/siRNA/DNA transfection methods
News & Updates
Booth participation at the Korean Molecular and Cellular Biology Society conference (Jeju ICC).
Attended the 2024 Vaccine Forum on mRNA vaccine research trends and development platforms at K-MEDI hub.
Exhibited at the national biochemistry and molecular biology society meeting.
Patent registered for ionizable lipids for LNP production (history lists patent registration in 2026).
Recipient of a regional venture industry award (Daegu-Gyeongbuk Advanced Venture Industry Award).
Company established in 2019 with seed investments reported in 2019 and 2022.
Booth participation at the Korean Molecular and Cellular Biology Society conference (Jeju ICC).
Attended the 2024 Vaccine Forum on mRNA vaccine research trends and development platforms at K-MEDI hub.
Exhibited at the national biochemistry and molecular biology society meeting.
Patent registered for ionizable lipids for LNP production (history lists patent registration in 2026).
Recipient of a regional venture industry award (Daegu-Gyeongbuk Advanced Venture Industry Award).
Company established in 2019 with seed investments reported in 2019 and 2022.